Method for expression of small antiviral RNA molecules...

Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S006120, C435S091100, C435S320100, C435S457000, C435S475000, C435S489000, C536S023100, C536S024320, C536S024500

Reexamination Certificate

active

07732207

ABSTRACT:
In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG.1A). The methods can be used to express double stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, that interfere with a viral life cycle by down regulating either the viral genome, a viral genome transcript, or a host cell that. In another aspect the invention provides methods for treating patients having suffering from infection, particularly infection with HIV. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle.

REFERENCES:
patent: 5650309 (1997-07-01), Wong-Stall et al.
patent: 5883081 (1999-03-01), Kraus et al.
patent: 6022962 (2000-02-01), Chowrira et al.
patent: 6060317 (2000-05-01), Malech
patent: 6096538 (2000-08-01), Kingsman
patent: 6218186 (2001-04-01), Choi et al.
patent: 6255071 (2001-07-01), Beach et al.
patent: 6274788 (2001-08-01), Kumar
patent: 6312956 (2001-11-01), Lane
patent: 6506559 (2003-01-01), Fire
patent: 6566083 (2003-05-01), Thastrup
patent: 6586208 (2003-07-01), Donahue
patent: 6635472 (2003-10-01), Lauermann
patent: 6664107 (2003-12-01), Mak
patent: 7195916 (2007-03-01), Qin et al.
patent: 2003/0059944 (2003-03-01), Lois-Caballe et al.
patent: 2003/0068821 (2003-04-01), Lois-Caballe et al.
patent: 2003/0124513 (2003-07-01), McSwiggen
patent: 2004/0072771 (2004-04-01), Symonds et al.
patent: 2008/0003682 (2008-01-01), Lois-Caballe et al.
Arendt et al., “Vector Systems for the Delivery of Small Interfering RNAs: Managing the RISC**”ChemBioChem, 4, pp. 1129-1136 (2003).
Banerjea Akhil et al., “Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages”,Molecular Therapy : The Journal of American Society of Gene Therapy, pp. 62-71, vol. 8, No. 1 (Jul. 2003).
Barton G M et al., “Retroviral delivery of small interfering RNA into primary cells”,Proceeding of the National Academy of Sciences of USA, pp. 14943-14945, vol. 99, No. 23, Washington, USA (Nov. 12, 2002).
Brummelkamp et al., “A system for Stable Expression of Short Interfering RNAs in Mammalian Cells,”Science, vol. 296 (Apr. 19, 2002).
Caplen N J et al., “Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems,”PNAS, vol. 98, No. 17 (Aug. 14, 2001).
Carmell et al., “The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis”,Genes&Development, pp. 2733-2742 (2002).
Chatterjee et al. “Dual-target inhibition of HIV-1 in virto by means of an adeno-associated antisense vector.”Science, vol. 258, pp. 1485-1488 (Nov. 27, 1992).
Consiglio et al., “In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice”,Nature Medicine, pp. 310-316, vol. 7, No. 3 (Mar. 2001).
Czauderna Frank et al., “Inducible shRNA expression for application in a prostate cancer mouse model”,Nucleic Acids Research, p. e127, vol. 31, No. 21 (Nov. 1, 2003).
De Palma et al., “In Vivo Targeting of Tumor Endothelial Cells by Systemic Delivery of Lentiviral Vectors”,Human Gene Therapy, pp. 1193-1206, vol. 14 (Aug. 10, 2003).
Devroe E. & Silver P A, “Retrovirus-delivered siRNA”,BMC Technology, pp. 1-5 (Aug. 28, 2002).
Filipowicz et al., “Post-transcriptional gene silencing by siRNAs and miRNAs”,Structural Biology, pp. 331-341 (2005).
Gatlin et al. “Long-term engraftment of nonobese diabetic/severe combined immunodeficient mice with human CD34+ cells transduced by a self-inactivating human immunodeficiency virus type I vector,”Human Gene Therapy, vol. 12, 1079-1089 (Jun. 2001).
Godwin et al. “Detection of targeted GFP-Hox gene fusions during mouse embryogenisis,”PNAS, vol. 95, pp. 13042-10347 (Oct. 1998).
Howard Hughes Medical Institute, “Pushing the Envelope” (Nov. 21, 1997).
Ilves et al., “Retroviral Vectors designed for targeted expression of RNA polymerases III-driven transcripts: a comparative study.”Gene, vol. 171, pp. 203-208 (1996).
Iwakuma et al., “Self-inactivating lentilviral vectors with U3 and U5 modifications,”Virology, vol. 261, pp. 120-132 (1999).
Jacque J-M et al., “Modulation of HIV-1 replication by RNA interference”,Nature, pp. 435-438, vol. 418, No. 6896, London Great Britton (Jul. 25, 2002).
Junker et al. “Reduction in replication of the human immunodeficiency virus type I in human T cell lines by polymerase III-driven transcription of chimeric tRNA-antisense RNA genes,”Antisense Research and Development, vol. 4, pp. 165-172 (1994).
Kafri et al. “Lentiviral Vectgors: Regulated gene expression,”Molecular Therapy, vol. 1, No. 6, 516-521 (Jun. 2000).
Lawrence D “RNAi could hold promise in the treatment of HIV,” The Lancet, vol. 359 (Jun. 8, 2002).
Lee N S et al., “Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells”,Nature Biotechnology, pp. 500-505, vol. 19 (May 2002).
Li et al., “Inhibition of HIV-1 infection by lentiviral vectors expressing pol III-promoted anti-HIV RNAs”,Molecular Therapy, Academic Press, pp. 196-206, vol. 8, No. 2, San Diego, CA, USA (Aug. 2003).
Lieberman et al., “Interfering with disease: opportunities and roadblocks to harnessing RNA interference,”Trends in Molecular Medicine, vol. 9, No. 9, pp. 397-403 (Sep. 2003).
Lois Carlos et al., “Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors”,Science, pp. 868-872, vol. 295, No. 5556 (Feb. 1, 2002).
Martinez L J, “Katy, bar the door! HIV entry inhibitors,”Research/Initiative/Treatment Action! (Jun. 2000).
Matsukura S et al., “Establishment of conditional vectors for hairpin siRNA knockdowns”,Nucleic Acids Research, pp. e77-1, vol. 31, No. 15, Oxford University (Aug. 1, 2003).
Miyagishi M et al., “U6 promoter-driven sirnas with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells”,Nature Biotechnology, pp. 497-500, vol. 19, No. 5, US (May 2002).
Miyoshi H. et al. “Development of a self-inactivating lentivirus vector”,Journal of Virology, pp. 8150-8157, vol. 72, No. 10 (1998).
Miyoshi et al., “Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector”,Medical Sciences, pp. 10319-10323, vol. 94 (Sep. 1997).
Mummidi et al., “The human CC chemokine Receptor 5 (CCR5) gene”Jour. Biol. Chem., vol. 272, p. 30662, col. 2, lines 11-13 (Oct. 5, 1997).
Naldini, L. et al., “In Vivo Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector”Science, vol. 272 (Apr. 12, 1996).
National Cancer Institute, “Scientists Suggest New Approaches for Development of AIDS Drugs and Vaccines”Charity Wire(Jun. 21, 1999).
Novina C D et al., “siRNA directed inhibition of HIV-1 infection”,Nature Medicine, pp. 681-686, vol. 8, No. 7 (Jul. 2002).
Ogueta et al., “Design and in vitro characterization of a single regulatory module for efficient control of gene expression in both plasmid DNA and a self-inactivating lentiviral vector,”Molecular Medicine, vol. 7, No. 8, 569-579 (2001).
Ohkawa J. et al., “Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter”,Human Gene Therapy, pp. 577-585, vol. 11, No. 4 (Mar. 1, 2000).
Paddison P J et al., “Short hairpin RNAs (shRNAs) induce sequence-specific silencing

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for expression of small antiviral RNA molecules... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for expression of small antiviral RNA molecules..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for expression of small antiviral RNA molecules... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4154434

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.